financial guidance

The company said it expects core molecular testing revenue between $115 million and $125 million and SARS-CoV-2 revenue between $15 million and $20 million.

For full-year 2020, the company expects revenues of approximately $417 million, which would be up 25 percent from a year ago.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

The firm's Diagnostics division expects to post $1.13 billion in revenues for fiscal Q1 2021, up 262 percent from $312.0 million in the year-ago period.

Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.

Diagnostics revenues were €32.5 million in Q3, up almost fivefold from €6.8 million last year, and included €27.4 million from commercial coronavirus testing.

The company said that in the second half of 2020, its core business, excluding COVID-19 clinical reagents and testing revenues, remained resilient despite lockdowns.

The firm now expects 2020 revenues to grow approximately 22 percent year over year and adjusted earnings per share of $2.13 to $2.14.

The company now expects organic revenues to grow 40 percent year over year in Q4, driven by its base business and sales related to the COVID-19 response.